Sanofi today said they would buy Synthorx (THOR US) for $2.5 billion in cash; oncology related. 

In my search to justify a US$2 billion market cap for RVX, this buyout is the most encouraging sign yet, that RVX will get a high price; at least as high as $2.5 billion. 

THOR was trading at $11 (US$330 million market cap) on October 28 2019 and the buyout share price is $68...6 times up.  That is about as close as you can get for RVX.  Hopefully, this breathes fresh life into RVX share price.

Here's hoping!

Iconoclast